The U.S. Health Secretary canceled $500 million in government-funded mRNA vaccine projects aimed at respiratory illnesses, drawing criticism from infectious disease experts who emphasize mRNA's speed advantage in pandemic response. Concerns arise that reverting to slower traditional vaccine platforms could hamper readiness for future pandemics and limit global vaccine access. Experts warned that older methods might cover only a quarter of the world population in prolonged outbreaks.